Elisabetta Teodori Selected Research

Acute Erythroblastic Leukemia (Erythroleukemia)

6/2019	Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
3/2018	Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
11/2014	Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.
1/2013	New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).
2/2010	Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.
2/2009	N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors.
2/2007	Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors.
11/2005	Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.
2/2005	Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisabetta Teodori Research Topics

Disease

9	Neoplasms (Cancer) 01/2022 - 01/2006
9	Acute Erythroblastic Leukemia (Erythroleukemia) 06/2019 - 02/2005
5	Breast Neoplasms (Breast Cancer) 12/2020 - 08/2015
3	Amnesia (Dissociative Amnesia) 04/2015 - 12/2008
3	Neuralgia (Stump Neuralgia) 04/2011 - 01/2004
2	Glaucoma 01/2022 - 05/2018
2	Leukemia 06/2019 - 01/2006
1	Pathologic Processes 04/2019
1	Hypersensitivity (Allergy) 01/2017
1	Leukemia L5178 12/2011
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2006
1	Lymphoma (Lymphomas) 01/2006
1	Multiple Myeloma 01/2006
1	Hematologic Neoplasms (Hematological Malignancy) 01/2006
1	Pain (Aches) 11/2004
1	Pheochromocytoma 11/2004

Drug/Important Bio-Agent (IBA)

8	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 02/2009
6	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2006
6	pirarubicinIBA 06/2019 - 02/2009
4	ATP-Binding Cassette Transporters (ABC Transporters)IBA 12/2020 - 08/2015
4	EstersIBA 01/2020 - 12/2011
4	multidrug resistance-associated protein 1IBA 06/2019 - 08/2015
3	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2020 - 12/2011
3	AminesIBA 01/2020 - 12/2011
3	Adenosine Triphosphate (ATP)IBA 01/2019 - 08/2015
3	AnthracyclinesIBA 02/2007 - 02/2005
3	Verapamil (Calan)FDA LinkGeneric 01/2006 - 02/2005
2	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 12/2020
2	CyclohexanolsIBA 01/2016 - 12/2011
2	Scopolamine (Hyoscine)FDA Link 04/2015 - 04/2011
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2022
1	AmidesIBA 12/2020
1	tariquidar (XR9576)IBA 01/2020
1	Carrier Proteins (Binding Protein)IBA 06/2019
1	Protein Isoforms (Isoforms)IBA 04/2019
1	DiureticsIBA 05/2018
1	Pharmaceutical PreparationsIBA 01/2017
1	Glutathione (Reduced Glutathione)IBA 01/2017
1	Nootropic Agents (Nootropics)IBA 04/2015
1	PiperazinesIBA 04/2015
1	Rhodamine 123IBA 12/2011
1	Adenosine Triphosphatases (ATPase)IBA 12/2011
1	Streptozocin (Streptozotocin)FDA Link 04/2011
1	Pregabalin (Lyrica)FDA Link 04/2011
1	CyclohexaneIBA 12/2008
1	Piracetam (Nootropil)IBA 12/2008
1	MM 36IBA 01/2006
1	N-Type Calcium Channels (N-Type Calcium Channel)IBA 11/2004
1	4-aminopiperidineIBA 11/2004
1	Analgesics (Analgesic Drugs)IBA 01/2004

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2019 - 01/2017
1	Therapeutics 01/2016